European equities traded in the US as American depositary receipts were tracking higher late Tuesday morning, rising 0.91% to 1,261.50 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and biopharmaceutical company Cellectis (CLLS), which advanced 20% and 9.5% respectively. They were followed by biopharmaceutical company Genfit (GNFT) and Spanish lender Banco Santander (SAN), which climbed 7.8% and 5% respectively.
The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and oil and gas company Eni (E), which lost 6.3% and 1.3% respectively. They were followed by telecommunications operator Telefonica (TEF) and oil and gas company TotalEnergies (TTE), which were down 0.7% and 0.6% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Akari Therapeutics (AKTX) and cruise line operator Carnival (CUK), which rose 9.5% and 7.1% respectively. They were followed by biopharmaceutical companies Verona Pharma (VRNA) and Mereo BioPharma Group (MREO), which advanced 3.9% and 3.8%respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and lender HSBC (HSBC), which dropped 8.6% and 1.9% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and biotechnology firm Trinity Biotech (TRIB), which fell 1.8% and 1.7% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.